Streetwise Reports Examines 15 Reasons Why Hemp Producer Elixinol Should Be in Your Portfolio

GlobeNewswire - finance.yahoo.com Posted 5 years ago
image

SAN FRANCISCO, Dec. 18, 2018 (GLOBE NEWSWIRE) -- The U.S. Congress passed the 2018 Farm Bill that legalizes hemp; the bill is expected to be signed by the President soon. Against this backdrop, Fincom Investment Partners profiles a hemp company whose largest market is the U.S.

Company mentioned:  Elixinol Global Ltd. (EXL:ASX; ELLXF:OTCQX)

Elixinol Global is a U.S.-focused, publicly traded, "pure play" hemp manufacturer, 85% focused on CBD. Investors with interest in hemp/cannabis, or wellness—and growth—may consider adding Elixinol to their portfolio. We believe CBD is part of a massive growing trend away from strong "meds" (like opioids) into more natural, less invasive health options.

CBD (non-intoxicant) "cannabidiol" market is booming. CBD is a cannabis related-compound, but does not contain THC (the "high" component in marijuana). There are no psychoactive effects, only natural health benefits. Numerous research studies show wide ranging benefits including inflammation, pain, anxiety, arthritis, diabetes, PTSD, infections, epilepsy, depression, alcoholism and MS.

Better odds with CBD. We find only three "investable," public, pure-play CBD companies having significant sales. The Canadian government lists 132 authorized cannabis producers. Who will pick the winner? CBD is easier—one can easily bet all the good horses.

Elixinol focuses more on the wholesale side, selling to many other CBD companies who then re-package the oil, while CWEB and CVSI sell mostly at independent nutrition retailers. All three are profitable, with strong growth, quality products, relatively similar sales and earnings, and all sell for a fraction of the big Canadian cannabis companies.

CBD "grows" on you. CBD benefits appear to increase as people age. We suspect this may relate to oxidative stress.

Continue reading this article: 15 Reasons Why Hemp Producer Elixinol Should Be in Your Portfolio 

About Streetwise Reports

Streetwise Reports shares investment ideas in many sectors. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.

DISCLOSURE:

The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.

Frederick Lacy: Fincom Investment Partners owns shares of the following companies mentioned in this article: Elixinol.

The full disclosure is provided at the article's end: 15 Reasons Why Hemp Producer Elixinol Should Be in Your Portfolio


For more information, please contact Carmen Guzman, [email protected].